The 2020 CX Report gathers trends on how business happens in the computational era by examining the tech stacks for marketing and products in the context of digital transformation.
A friend who’s managing her spouse’s onset of Alzheimer shared the term “anticipatory grief” with me — that was a new term I hadn’t heard about.
I then asked her the question, “Do people want to know what disease they might be carrying?” To which she said, “People want to know in different amounts.” I thought this was the most wise thing I’ve heard in a long time.
Someone who loves to go deep, wants to know everything. Whereas someone who can’t handle or manage the situation might want to know zero/zilch.
We then talked about how managing the situation of a loved one taking on Alzheimer’s requires her to “bear it” — which takes on both an intellectual and physical toll. Her partner will eventually fade away, but my friend will need to navigate the different form of grief as her memory fades.
My friend then went on to describe how a clinical trial works for an experimental drug, and how it falls into three phases:
- Safety [it shouldn’t hurt anybody]
- Safety and Efficacy [it didn’t hurt someone and did it do something in a sample group?]
- Does it work? To what degree does it work? [does it reduce the symptoms or does it actually address root cause — to what degree is it going to work or stop working]
If a drug passes these three phases it then gets to be FDA-approved. Wow — I learned so much amidst hearing something so sad. Life is meant to be lived while you’ve got it. Live! —JM
Sign up for the CX Briefing with no more than 2020 characters, zero images, and all in plain-text.